Our findings confirm the notion that refining patient selection based on the mutational and signalling status of relevant oncogenes and tumour suppressors such as PTEN is a powerful clinical tool for the targeted application of emerging agents in melanoma treatment. Here, PTEN is linked to neoplasm.